Defence Therapeutics: Developing Next Generation Therapies to Combat Cancer with Propietary ACCUM™ Technology

Stocks to Invest in: Biotech

Cancer treatment along with other infectious diseases need clinical solutions and this company may have one. BTV interviews Defense Therapeutics to learn about their proprietary ACCUM™ technology and its proven ability to deliver treatment drugs to diseased cells.

Defence Therapeutics is a biotechnology company engaged in the business of research and development with a focus on enhancing delivery of infectious disease-specific therapies.

The company claims that their propietary ACCUM™ technology can optimize efficacy by up to 200% as well as treat several types of cancers.

"Defence has a technology that I personally call a solution looking for a problem," says Dr. Moutih Rafei, VP Research & Development and Director.

 "Usually when you have a company that has a drug or a specific product, that product is specific for one target, one indication. The beauty of the ACCUM technology, it's extremely versatile."

Cancer treatment along with other infectious diseases need clinical solutions and this company may have one. BTV interviews Defense Therapeutics to learn about their proprietary ACCUM™ technology and its proven ability to deliver treatment drugs to diseased cells.

Currently, Defence is actively working with a group of consultants in order to initiate a Phase One trial for early next year with the goal of completion by early 2024.

‍

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

‍